The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
about
Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGelNeoplasia: Where We Have Been and Where We Are GoingNeoplasia: the second decade.Cancer therapy with bispecific antibodies: Clinical experience.Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropinImmunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL).Targeted erythropoietin selectively stimulates red blood cell expansion in vivo.Tumor necrosis factor and cancer, buddies or foes?Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.Death receptors as targets for anti-cancer therapy.Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.Neoplasia: An Anniversary of Progress.
P2860
Q27343143-DA2CC424-AA2C-4029-AA09-D191B7176F8CQ28395095-FDE24CD0-FFD6-4FFF-BAD2-06B154881FCEQ30484000-BEFAF201-0F9B-43AC-A8CA-EBC2304DB4F7Q34118856-BAE1A325-EDCD-4791-B4C6-BC8EEBABED37Q35233582-E1357F57-5C34-4262-83B1-8538DE0F0647Q35918856-D92D322B-288D-4CBF-A73E-49AC790B8FF6Q36179663-14030578-9678-4FEF-BFDB-4DEB291C3531Q36412875-C81679BF-9337-4284-9782-0FE0E525027CQ36905103-68844D56-3FE5-4E43-AA83-2BB433888A51Q37073092-9E000D18-C95E-47E7-8C71-8EEE1868B8F3Q37220415-CC1D4503-7D54-4ACB-BEB1-563D8C55571BQ37390893-631806C6-69FA-4101-B335-4C4E7E52EB7DQ41990475-B91E8576-06ED-44E8-B95E-52490DC8FCA9Q46932476-EA24AAF4-4409-4D98-AC21-09A3E32945EE
P2860
The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The antimelanoma immunocytokin ...... gainst human tumor xenografts.
@ast
The antimelanoma immunocytokin ...... gainst human tumor xenografts.
@en
type
label
The antimelanoma immunocytokin ...... gainst human tumor xenografts.
@ast
The antimelanoma immunocytokin ...... gainst human tumor xenografts.
@en
prefLabel
The antimelanoma immunocytokin ...... gainst human tumor xenografts.
@ast
The antimelanoma immunocytokin ...... gainst human tumor xenografts.
@en
P2093
P2860
P356
P1433
P1476
The antimelanoma immunocytokin ...... gainst human tumor xenografts.
@en
P2093
Carolyn S Van Pelt
Lawrence H Cheung
Michael G Rosenblum
Qingping Wu
Weihe Zhang
Yuying Liu
P2860
P304
P356
10.1593/NEO.06121
P577
2006-05-01T00:00:00Z